# A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)

> **NCT04787328** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Medullary Thyroid Carcinoma

## Interventions

- **DRUG:** HA121-28 tablets

## Key facts

- **NCT ID:** NCT04787328
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-13
- **Primary completion:** 2023-03
- **Final completion:** 2025-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04787328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04787328, "A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04787328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*